The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has rocketed over 2019 as excitement mounts over the biotech researcher’s potential to commercialise drugs designed to treat inflammatory conditions such as osteoarthritis.
On September 10 2019 it told investors that its ‘investigational new drug’ (IND) application has been cleared by the US healthcare regulator the FDA.
In effect it now has the green light to proceed with Phase III trials that could provide the clinical evidence needed to commercialise its pentosan polysulfate sodium-based drug to treat osteoarthritis.
According to Paradigm bulls or evangelists its pentosan polysulfate sodium-based drug has more than 1,000 possible indications in treating common human medical conditions. So in theory the company has some eye-watering potential.
As at 30 June 2019 it had $73.2 million cash on hand to show it’s a credible operator that the market has now bid up to a value around $491 million based on a $2.55 share price and around 192.5 million shares issue.
It also has the option to partner with big pharma to shoulder some of the high costs of Phase III and other clinical trials. Any partnership would be in return for some sort of financial or equity-related interest.
The company has no sales as yet and remains a speculative bet only suitable for experienced investors confident in their research.
As a final disclaimer it’s also worth remembering these kind of stocks can often rise on excitement before crashing on reality, as such they can fall into the ‘buy the rumour, sell the news’ category.
If there's one thing for sure, 2020 has been the year we embraced sanitisation. Scott Phillips has discovered a little-known Australian healthcare company could be set to reap the rewards of the post-covid world.
Better yet, this fast-growing company is currently trading at a 30% discount from its highs. Scott believes in this stock so much, he's staked $209k of our own company money on it. Forget 'buy now pay later', this stock could be the next hot stock on the ASX.
Scott and his team have published a detailed report on this tiny ASX stock. Find out how you can access our TOP healthcare stock today!
As of 2.11.2020
You can find Tom on Twitter @tommyr345
The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
- On a serendipitous day, Tom Richardson is leaving the building – December 17, 2019 11:55am
- Why Aerometrex shares have doubled their IPO price – December 16, 2019 4:32pm
- Why the National Veterinary Care share price is going nuts today – December 16, 2019 3:39pm